Inhibitor Treatment in Hemophilia A and B
Online CME Activity
This activity is published in the journal Haemophilia, Vol 12, s6, Dec 2006 (subscription req'd): "Inhibitor Treatment in Hemophilia A and B: Proceedings of the 2006 International Consensus Conference"
Up to 3 hours of AMA PRA Category 1 Credit™
Release date: December 2006 Valid through: November 2008
Course Material: CME Activity - PDF
Receiving CME Credit
To receive online CME credit for this activity, click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This activity is designed to meet the educational needs of hematologists and other medical professionals who wish to increase their knowledge regarding advances in evaluating and treating inhibitors in patients with hemophilia A and B.
Educational Objectives
After reading the course material and taking the post-test, participants should be able to:
- Discuss new data on inhibitor biology as it relates to the development of inhibitors to Factor VIII and IX.
- Evaluate appropriate approaches to the diagnosis and characterization of inhibitors to Factor VIII and IX.
- Assess opportunities to reduce incidence and complications related to inhibitors.
- Assess appropriate treatment approaches to acute bleeds.
- Discuss alternative approaches to immune tolerance induction.
Educational Need
Our understanding of inhibitor biology in hemophilia A and B has increased dramatically over the past five years, contributing to new approaches to diagnosis, characterization, prevention and bleed management with potentially important implications for patient care. The purpose of this educational program is to bring together leaders in the field to review and evaluate current data, to summarize and assess the most promising ongoing research, and to identify priorities for future research. This will help clinical leaders as they plan future therapies and will help participants in the journal-based CME program to better assess existing and potential new approaches to inhibitor treatment.
Sponsorship and Accreditation
This journal-based CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. (InforMEDical). InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this activity.
Educational Grant Support
This activity is based on a symposium held March 24-25, 2006, in Cambridge, Massachusetts, USA. This is activity is supported by educational grants provided by Baxter Healthcare, Bayer Healthcare, Grifols, Wyeth Pharmaceuticals and ZLB Behring.
Credit Designation
InforMEDical designates this continuing medical education activity for up to 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Financial Disclosure
The program faculty have reported the following financial relationships with commercial pharmaceutical, device, biotechnology and/or blood products companies: Jan Astermark: Nothing to disclose. Erik Berntorp: Nothing to disclose. Victor S. Blanchette: Bayer: advisory board, honorarium; Baxter: honorarium, steering committee; Novo Nordisk: honorarium; Wyeth: honorarium. Peter W. Collins: Baxter: consultant, Speakers’ Bureau; Novo Nordisk: Speakers’ Bureau. Carmen Escuriola: Nothing to disclose. Donna DiMichele: Baxter: grant funding; Bayer: grant funding; Grifols: grant funding; Wyeth: industry-sponsored trial; ZLB Behring: grant funding. Charles R.M. Hay: Baxter: clinical trail, Speakers’ Bureau; Bayer: advisory committee, Speakers’ Bureau; Wyeth: advisory committee, research support, Speakers’ Bureau. W. Keith Hoots: Baxter: research support, Speakers’ Bureau; Bayer: research support; Grifols: research support; Novo Nordisk: research support, Speakers’ Bureau; Wyeth: research support; ZLB Behring: research support. Cindy A. Leissinger: Baxter: research grant, Speakers’ Bureau; Bayer: consultant; Grifols: consultant; Wyeth: consultant; ZLB Behring: consultant. Claude Negrier: Baxter: consulting, research support; Novo Nordisk: research support. Johannes Oldenburg: Baxter: consultant, research grant; Bayer: consultant; ZLB Behring: consultant. Kathelijne Peerlinck: Nothing to disclose. Mark T. Reding: Nothing to disclose. Amy Shapiro: Nothing to disclose.